Randomized Controlled Trial of Losartan for inpatients with COVID-19

About this Study

Evaluation of the impact of early losartan compared to placebo on the change in respiratory failure in inpatients diagnosed with COVID19 requiring hospital admission.

Sponsor Protocol ID:HRP-590
IRB Number:2020-0135
Closed for Enrollment
Interventional
Phase 2
April 16, 2020
Eligibility Criteria
18 years old
Both Male and Female
No
No
No

Inclusion Criteria(1) Presumptive positive lab test for COVID-19; 
(2) ≥18 years of age; 
(3) Hospital admission with a respiratory SOFA >=1 and increased oxygen requirement compared to baseline among those on home oxygen; and
(4) Randomization within 24 hours of presentation of hospital admission or within 48 hours of a positive test result, whichever is later.

Exclusion Criteria(1) Randomization > 24 hours of admission order or 48 hours of a positive test result, whichever is later;
(2) Currently taking an ACEi or ARB; 
(3) Prior reaction or intolerance to an ARB or ACEi; 
(4) Pregnant or breastfeeding; 
(5) History of kidney disease or severe liver disease; 
(6) Severe dehydration; 
(7) Most recent mean arterial blood pressure prior to enrollment
(8) Potassium >5.0 within 24 hours prior to randomization unless a repeat value was
(9) Treatment with aliskiren; and
10) Enrollment in another blinded randomized clinical trial for COVID.

Categories Click category to view its trials.
COVID-19 (Coronavirus)
Participating Locations
University Hospital - UMMC
Contact Information
Contact Name: Rebekah Peacock
Phone Number: 601-984-5570
Email: rpeacock@umc.edu
Principal Investigator:Alan Jones
How to participate in our Clinical Trials